Disease-Free Survival Not Improved With Intrathecal Triple Therapy in B-Cell ALL
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
Acute Lymphoblastic Leukemia
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Novel Pediatric Disease Risk Index in Patients With ALL, AML for Allogeneic Hematopoietic Cell Transplantation
Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
Managing Pegasparaginase Toxicities in Adults With Acute Lymphoblastic Leukemia
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
Real-World Trends in the Assessment of Minimum Residual Disease in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma
In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.
CAR-T in ALL: Records Reveal Direct Costs for Hospitalization Approach $300K
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981.
CAR-NK Cells Make Their Debut in Hematologic Cancers
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
